Reporting of safety results in published reports of randomized controlled trials

Archives of Internal Medicine

Volumn 169, Issue 19, 2009, Pages 1756-1761

  Pitrou, Isabelle ^a   Boutron, Isabelle ^a   Ahmad, Nizar ^a   Ravaud, Philippe ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; CLINICAL RESEARCH; HEALTH CARE POLICY; HEALTH HAZARD; MEDICAL LITERATURE; PATIENT SAFETY; PRIORITY JOURNAL; RATING SCALE;

EID: 70350489859     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.306     Document Type: Article

References (20)

1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437-443. (Pubitemid 32097262)
2. Ioannidis JP, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet. 1998;352(9142):1752-1753.
3. Ioannidis JP, Lau J. Improving safety reporting from randomised trials. Drug Saf. 2002;25(2):77-84. (Pubitemid 34261183)
4. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials: a systematic survey. BMC Clin Pharmacol. 2001;1:3. (Pubitemid 38751336)
5. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry. 2004;161(9): 1692-1697. (Pubitemid 39201468)
6. Bryant J, Loveman E, Cave C, Chase D, Milne R. Endocrinology trial design: adverse event reporting in randomised controlled trials of recombinant human GH in GH-deficient adults. J Endocrinol. 2002;175(2):545-552. (Pubitemid 35414400)
7. Ethgen M, Boutron I, Baron G, Giraudeau B, Sibilia J, Ravaud P. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med. 2005;143(1):20-25. (Pubitemid 40923331)
8. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al, "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.
9. N Engl J Med. 2005;353(26):2813-2814.
10. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006;354(11):1193.
11. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ. 2007;334(7585):120-123.
12. Altman DG, Schulz KF, Moher D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8): 663-694.
13. Moher D, Schulz KF, Altman DG; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134(8):657-662. (Pubitemid 32322244)
14. Ioannidis JP, Evans SJ, Gotzsche PC, et al; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
15. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. JAMA. 2002; 287(21):2805-2808. (Pubitemid 34591969)
16. Schriger DL, Sinha R, Schroter S, Liu PY, Altman DG. From submission to publication: a retrospective review of the tables and figures in a cohort of randomized controlled trials submitted to the British Medical Journal. Ann Emerg Med. 2006;48(6):750-756. (Pubitemid 44738147)
17. Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol. 2009;62(6):609-616.
18. Ioannidis JP, Mulrow CD, Goodman SN. Adverse events: the more you search, the more you find. Ann Intern Med. 2006;144(4):298-300. (Pubitemid 46768214)
19. Jonville-Béra AP, Giraudeau B, Autret-Leca E. Reporting of drug tolerance in randomized clinical trials: when data conflict with authors' conclusions. Ann Intern Med. 2006;144(4):306-307. (Pubitemid 46768224)
20. Tugwell P, Judd MG, Fries JF, Singh G, Wells GA. Powering our way to the elusive side effect: a composite outcome "basket" of predefined designated endpoints in each organ system should be included in all controlled trials. J Clin Epidemiol. 2005;58(8):785-790.